According to the latest market report published by Credence Research, Inc. ?Nuclear Medicine/ Radiopharmaceuticals Market - Growth, Future Prospects and Competitive Analysis, 2017 - 2025? the global nuclear medicine/ radiopharmaceuticals market was valued at US$ 4.82 Bn in 2016, and is expected to reach US$ 7.78 Bn by 2025, expanding at a CAGR of 5.5% from 2017 to 2025.

Browse the full report Nuclear Medicine/ Radiopharmaceuticals Market - Growth, Future Prospects and Competitive Analysis, 2017 ? 2025 report athttp://www.credenceresearch.com/report/nuclear-medicine-radiopharmaceuticals-market

Market Insights

Nuclear medicine/ radiopharmaceuticals is a drug that can be used either for diagnostic or therapeutic purposes. Advantage such as targeted therapeutic irradiation with lower adverse effects and cost effective treatment option are prime factors that are driving the nuclear medicine/radiopharmaceuticals market growth. Nuclear medicine/ radiopharmaceuticals is segmented on the basis of application such as therapeutic (thyroid, oncology, bone metastasis and other applications) and diagnostics application (cardiology, thyroid, oncology and other therapeutic application). It is estimated that, therapeutic application will show fastest market growth during forecast period due to its advantages over the traditional drug therapies such as targeted therapeutic action and lower side effects. Radiopharmaceuticals applications in cardiology and oncology is anticipated to grow significantly during forecast period due to its increasing applicability in diagnosis of the disease; furthermore, growing prevalence of these disease will fuel the market growth. Radiopharmaceuticals market is categorized on the basis of type such as diagnostics radiopharmaceuticals (SPECT and PET) and therapeutic Radiopharmaceutical (beta emitter, alpha emitter and brachytherapy). It is observed that, in the base year 2016, diagnostic radiopharmaceutical is major revenue generating segment, due to the rising incidence of cancer and cardiac disease, improved affordability, more precise technique and advancement in PET and SPECT scan. Radiopharmaceuticals market is currently dominated by North America due to technological advancement, higher investment in R&D activities, presence of large number of biopharmaceutical industries and research institutes. However, Asia Pacific will show fastest market growth due to increasing government investments in the life sciences sector and increasing partnership of key players with local manufacturer, and rapidly expanding life science industries will witness phenomenal growth.

Market Competition Assessment:  

The nuclear medicine/ radiopharmaceuticals market is observed to be highly competitive and comprises large number of players. However, the market is currently dominated by few players such as Advanced Accelerator Applications S.A., Bayer AG, Bracco Imaging S.p.A., Cardinal Health, Inc., GE Healthcare, IBA Molecular Imaging, Lantheus Medical Imaging Inc., Mallinckrodt plc., Medtronic, plc., Nordion, Inc., NTP Radioisotopes SOC Ltd., Segami Corporation and others.

Key Market Movements:

• Factors such as increase in number of chronic disease, technological advancement and increasing awareness of radiopharmaceuticals are primarily driving the growth of nuclear medicine/ radiopharmaceuticals market globally
• The major opportunity radiopharmaceutical market is due to high unmet needs for treatment of various forms of cancer and this would expected to drive the nuclear medicine/ radiopharmaceuticals market growth during forecast period.

Browse the full report Nuclear Medicine/ Radiopharmaceuticals Market - Growth, Future Prospects and Competitive Analysis, 2017 ? 2025 report athttp://www.credenceresearch.com/report/nuclear-medicine-radiopharmaceuticals-market

Nuclear medicine is a medical specialty involving the application of radioactive substances in the diagnosis and treatment of disease. Nuclear medicine, in a sense, is "radiology done inside out" or "endoradiology" because it records radiation emitting from within the body rather than radiation that is generated by external sources like X-rays. In addition, nuclear medicine scans differ from radiology as the emphasis is not on imaging anatomy but the function and for such reason, it is called a physiological imaging modality. Single photon emission computed tomography (SPECT) and positron emission tomography (PET) scans are the two most common imaging modalities in nuclear medicine.

Radiopharmaceuticals, or medicinal radiocompounds, are a group of pharmaceutical drugs which have radioactivity. Radiopharmaceuticals can be used as diagnostic and therapeutic agents. Radiopharmaceuticals emit radiation themselves, which is different from contrast media which absorb or alter external electromagnetism or ultrasound. Radiopharmacology is the branch of pharmacology that specializes in these agents.

The main group of these compounds  are the radiotracers used to diagnose dysfunction in body tissues. While not all medical isotopes are radioactive, radiopharmaceuticals are the oldest and still most common such drugs. Source: Wikipedia

 Latest Reports:

Microbiome Sequencing Services Market: http://www.credenceresearch.com/press/global-microbiome-sequencing-services-market

Blog: https://globenewswire.com/news-release/2018/03/13/1421126/0/en/Direct-To-Consumer-DTC-Genetic-Testing-Market-is-Expected-to-Grow-at-The-CAGR-of-19-4-During-2018-2026-Credence-Research.html

About:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared for this task.

Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429
SAN JOSE, CA 95103 US
E-mail: sales@credenceresearch.com
Ph: 1-800-361-8290
Web: http://www.credenceresearch.com